Top

Published in:

Open Access 01-12-2022 | Glioblastoma | Review

Glioblastoma vaccine tumor therapy research progress

Authors: Tong Zhao, Chunwang Li, Hongliang Ge, Yuanxiang Lin, Dezhi Kang

Published in: Chinese Neurosurgical Journal | Issue 1/2022

Abstract

Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults. The prognosis for late-stage glioblastoma (World Health Organization grade IV astrocytic glioma) is very poor. Novel treatment options are sought after and evaluated by clinicians and researchers, and remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy. However, the treatment of glioblastoma remains extremely difficult and it can extend the lives of patients by only a few months. There has been notable progress in the field of immunotherapy, particularly with the use of tumor vaccines, for treating glioblastoma; especially peptide vaccines and cell-based vaccines such as dendritic cell vaccines and tumor cell vaccines. However, the results of the current clinical trials for vaccination are not satisfactory. This article reviews the progress in the development of vaccines for glioblastoma.

Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016;375(2):263–73. https://doi.org/10.1016/j.canlet.2016.01.024.CrossRefPubMed

Louis D, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMed

Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330.CrossRefPubMed

Gilbert M, Wang M, Aldape K, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–91. https://doi.org/10.1200/JCO.2013.49.6968.CrossRefPubMedPubMedCentral

Patel A, Tirosh I, Trombetta J, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, NY). 2014;344:1396–401.CrossRef

Quail D, Bowman R, Akkari L, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science (New York, NY). 2016;352:aad3018.CrossRef

Hodges T, Ott M, Xiu J, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology. 2017;19(8):1047–57. https://doi.org/10.1093/neuonc/nox026.CrossRefPubMedPubMedCentral

Bigner D, Pitts O, Wikstrand C. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg. 1981;55(1):32–42. https://doi.org/10.3171/jns.1981.55.1.0032.CrossRefPubMed

Heimberger A, Crotty L, Archer G, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247–54.PubMed

10.

Schuster J, Lai R, Recht L, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-oncology. 2015;17(6):854–61. https://doi.org/10.1093/neuonc/nou348.CrossRefPubMedPubMedCentral

11.

Weller M, Butowski N, Tran D, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–85. https://doi.org/10.1016/S1470-2045(17)30517-X.CrossRefPubMed

12.

Yan H, Parsons D, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73. https://doi.org/10.1056/NEJMoa0808710.CrossRefPubMedPubMedCentral

13.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–7. https://doi.org/10.1038/nature13387.CrossRefPubMed

14.

Sampson J, Heimberger A, Archer G, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–9. https://doi.org/10.1200/JCO.2010.28.6963.CrossRefPubMedPubMedCentral

15.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5. https://doi.org/10.1038/s41586-018-0810-y.CrossRefPubMed

16.

Keskin D, Anandappa A, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–9. https://doi.org/10.1038/s41586-018-0792-9.CrossRefPubMed

17.

Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014;40(5):642–56. https://doi.org/10.1016/j.immuni.2014.04.016.CrossRefPubMed

18.

Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9(1):271–96. https://doi.org/10.1146/annurev.iy.09.040191.001415.CrossRefPubMed

19.

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77. https://doi.org/10.1038/nrc3258.CrossRefPubMedPubMedCentral

20.

Kantoff P, Higano C, Shore N, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. https://doi.org/10.1056/NEJMoa1001294.CrossRefPubMed

21.

Nair S, Archer G, Tedder T. Isolation and generation of human dendritic cells. Curr Protoc Immunol. 2012; Unit7.32.

22.

Strome S, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002;62(6):1884–9.PubMed

23.

Fecci P, Heimberger A, Sampson J. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014;20(22):5620–9. https://doi.org/10.1158/1078-0432.CCR-14-0832.CrossRefPubMedPubMedCentral

24.

Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018;67(11):1777–88. https://doi.org/10.1007/s00262-018-2232-y.CrossRefPubMed

25.

Liau L, Prins R, Kiertscher S, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515–25. https://doi.org/10.1158/1078-0432.CCR-05-0464.CrossRefPubMed

26.

Mitchell D, Batich K, Gunn M, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519(7543):366–9. https://doi.org/10.1038/nature14320.CrossRefPubMedPubMedCentral

27.

Parney I, Chang L, Farr-Jones M, Hao C, Smylie M, Petruk K. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol. 2006;78(1):71–80. https://doi.org/10.1007/s11060-005-9058-0.CrossRefPubMed

28.

Curry W, Gorrepati R, Piesche M, et al. Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016;22(12):2885–96. https://doi.org/10.1158/1078-0432.CCR-15-2163.CrossRefPubMedPubMedCentral

29.

Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Takano S, Enomoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 2007;98(8):1226–33. https://doi.org/10.1111/j.1349-7006.2007.00518.x.CrossRefPubMed

30.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014;121(3):543–53. https://doi.org/10.3171/2014.5.JNS132392.CrossRefPubMed

31.

Polikarpov D, Campbell D, McRobb L, et al. Near-infrared molecular imaging of glioblastoma by miltuximab-IRDye800CW as a potential tool for fluorescence-guided surgery. Cancers. 2020;12(4). https://doi.org/10.3390/cancers12040984.

32.

Dinevska M, Gazibegovic N, Morokoff A, et al. Inhibition of radiation and temozolomide-induced glioblastoma invadopodia activity using ion channel drugs. Cancers. 2020;12(10). https://doi.org/10.3390/cancers12102888.

33.

Ahmed S, Hasan M, Aschner M, et al. Therapeutic potential of marine peptides in glioblastoma: mechanistic insights. Cell Signal. 2021;110142:110142. https://doi.org/10.1016/j.cellsig.2021.110142.CrossRef

Title: Glioblastoma vaccine tumor therapy research progress
Authors: Tong Zhao
Chunwang Li
Hongliang Ge
Yuanxiang Lin
Dezhi Kang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Glioma
Glioma
Glioma
Published in: Chinese Neurosurgical Journal / Issue 1/2022
Electronic ISSN: 2057-4967
DOI: https://doi.org/10.1186/s41016-021-00269-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Glioblastoma vaccine tumor therapy research progress

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Multimodality treatment for brain arteriovenous malformation in Mainland China: design, rationale, and baseline patient characteristics of a nationwide multicenter prospective registry

ABC/2 formula for “bedside” postoperative pneumocephalus volume measurement

Risk factors and outcomes of postoperative stroke in surgical treatment for giant intracranial aneurysms

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma

New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis

Prediction of high infiltration levels in pituitary adenoma using MRI-based radiomics and machine learning